Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malig
about
Immunotoxin Therapies for the Treatment of Epidermal Growth Factor Receptor-Dependent CancersCurrent Understanding on EGFR and Wnt/β-Catenin Signaling in Glioma and Their Possible CrosstalkToxin-based targeted therapy for malignant brain tumorsToxin-based therapeutic approachesThe potential of polymeric micelles in the context of glioblastoma therapy.Therapeutic strategies to improve drug delivery across the blood-brain barrier.Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma.Site-specific opening of the blood-brain barrier.Neurosurgical oncology: advances in operative technologies and adjuncts.Combining cytotoxic and immune-mediated gene therapy to treat brain tumorsConvection-enhanced delivery of targeted toxins for malignant glioma.Present and potential future issues in glioblastoma treatment.Disruption of the blood-brain barrier following ALA-mediated photodynamic therapyTargeted delivery of bleomycin to the brain using photo-chemical internalization of Clostridium perfringens epsilon prototoxin.EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cellsInterstitial infusion of glioma-targeted recombinant immunotoxin 8H9scFv-PE38.Advances in strategies to improve drug delivery to brain tumors.Anatomical differences determine distribution of adenovirus after convection-enhanced delivery to the rat brain.Experimental approaches for the treatment of malignant gliomas.Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study.Abrin immunotoxin: targeted cytotoxicity and intracellular trafficking pathway.Intracellular trafficking considerations in the development of natural ligand-drug molecular conjugates for cancer.Clinical development of experimental therapies for malignant glioma.Gene therapy and targeted toxins for glioma.Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: case studyClinical utility of a patient-specific algorithm for simulating intracerebral drug infusionsMonoclonal antibodies for brain tumour treatment.Therapy for recurrent malignant glioma in adults.Recent developments on immunotherapy for brain cancer.Targeted toxins for glioblastoma multiforme: pre-clinical studies and clinical implementation.Delivery systems and molecular targets of mechanism-based therapies for GBM.Small molecule and monoclonal antibody therapies in neurooncology.Protein toxins: intracellular trafficking for targeted therapy.Local delivery of antineoplastic agents by controlled-release polymers for the treatment of malignant brain tumours.Tumor immunology, immunomics and targeted immunotherapy for central nervous system malignancies.Convection-enhanced and local delivery of targeted cytotoxins in the treatment of malignant gliomas.Convection-enhanced delivery of interleukin-13 receptor-directed cytotoxin for malignant glioma therapy.Malignant gliomas: strategies to increase the effectiveness of targeted molecular treatment.Convection-enhanced delivery in the treatment of malignant glioma.Issues related to targeted delivery of proteins and peptides.
P2860
Q26751473-6963FA88-06C0-4C10-A619-5FD5CC7D31ECQ26865911-07B91EB9-1F54-4E25-88FC-A4A264B98E83Q27006226-0C3625C2-22DE-4708-9CE9-3DF0BF422544Q27013664-FAAF82E2-C3CD-46C4-92CF-919F919A9F6BQ27693205-608B14E4-C1F0-455E-B88B-6AD3B22DA21CQ30407443-125FC169-30CB-47C1-877E-C0927D870A52Q30431291-061A43F0-6C57-41FE-89AA-66139CAA51F8Q30434041-61C9482A-91EA-48DB-BF0B-85BC01C2A86AQ30833619-4C8429BD-B645-4B57-B8DD-FD3A4B2DA966Q31013320-A8B04F2D-C939-4B1C-8100-278D6A821957Q31038118-0BB7209D-700F-4C14-83AC-1E11A5B7331EQ31043603-B71A1C11-18D1-4EBD-AD84-E1BBA1DCDD21Q33370158-A408A442-368E-4064-B988-3289CB327B87Q33464353-F896B96C-88A7-4B3E-B824-BE3C5232C67DQ33758468-7F5E81B6-8792-412A-A3DA-200AF5DA0175Q33828459-4892309B-0A17-4039-8AE3-A88997CAB480Q34000631-AD3565C7-6FC2-4762-BF44-B43E88F6FD69Q34055421-FF916D05-3E5B-4A23-A7F8-7642AAEAF9F5Q34127138-A49FFBAC-2DBA-482F-BEC4-7467D69D87DAQ34132839-6486A0E8-C1FA-456B-9EB0-4D43E0446698Q34614897-4B46BC61-B781-45F2-98A2-D2492ED15769Q34751465-AAC4D489-D6E1-4163-BEEC-F1F3BB6F62E6Q34782295-39441A5E-729B-4FA3-B48D-BB6C882CF22DQ35118933-59BBAB3D-4C67-441A-94A3-2DB3062755A6Q35799893-FC9DBA5C-D4C6-4858-8E45-19E2948F6722Q35870471-D0BCA298-9595-4DA3-94F7-DC9205FAE45CQ35873775-6B7142B8-584E-4622-A3D6-74BF62161C55Q35918439-35AC67D9-CCB1-4BEE-9B00-14A182687069Q35992355-AD5C4F99-17D5-4E2E-8CF7-862E431599CFQ35999648-6BD15E84-2852-4F8F-A16E-028C5D51397CQ36107160-220CB19D-9B97-4A35-BE9F-937811B8BD6FQ36108621-CA80E6E6-BF45-4C36-9B2A-0A538FEA936AQ36132002-1EC06C19-3ED6-46FF-993E-1469FF53E53CQ36150422-F1290AA7-9ADF-4CCA-9126-9604F5E1959EQ36273691-AD8E8AA7-FAC0-43D6-80D1-6520A0526C34Q36478643-8B5E3518-3B42-46EC-881B-B10E597A2D73Q36478656-9BE16618-6EF5-45DA-B187-4BFA8E1465B9Q36499234-12DD72E2-5FCC-4D76-9613-047A081FB705Q36523379-CB0FC413-22DA-4511-AAA3-6A86A543A2BCQ36616311-26DA50BD-6D94-4F1D-8ED0-D9915F0BF3BF
P2860
Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malig
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Progress report of a Phase I s ...... 38) for the treatment of malig
@en
Progress report of a Phase I s ...... of transforming growth factor
@nl
type
label
Progress report of a Phase I s ...... 38) for the treatment of malig
@en
Progress report of a Phase I s ...... of transforming growth factor
@nl
prefLabel
Progress report of a Phase I s ...... 38) for the treatment of malig
@en
Progress report of a Phase I s ...... of transforming growth factor
@nl
P2093
P50
P356
P1476
Progress report of a Phase I s ...... 38) for the treatment of malig
@en
P2093
Alison Paolino
Carol Wikstrand
Gamal Akabani
Gary E Archer
Ira Pastan
James E Herndon
James Provenzale
Jennifer Quinn
Jeremy Rich
P2888
P356
10.1023/A:1026290315809
P577
2003-10-01T00:00:00Z
P6179
1053441536